Lacomax50 mg

Lacomax is an antiepileptic drug (AED) with the following evidence-based indications:

Established / FDA-approved uses

• Monotherapy treatment of partial-onset (focal) seizures in patients aged 4 years and older.
• Adjunctive (add-on) therapy for partial-onset seizures in patients aged 1 month and older, used together with other antiepileptic drugs.
• Adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older with idiopathic generalized epilepsy.

Off-label / adjunct clinical use (not formally approved but supported by clinical practice)

• Status epilepticus refractory to first-line agents, used as an intravenous adjunct under specialist supervision.
• Neuropathic pain management (e.g., diabetic peripheral neuropathy), though evidence is limited and this is not an approved indication in most markets.

Use of Lacomax for any indication should be guided and monitored by a physician, generally a neurologist.

Each tablet, oral solution, or intravenous injection of Lacosamide contains Lacosamide as the active pharmaceutical ingredient. It is available as film-coated tablets (typically 50 mg and 100 mg), an oral solution (typically 50 mg/5 mL for patients who cannot swallow tablets or for weight-based dosing), and a solution for intravenous infusion for use when oral administration is temporarily not feasible.

Lacomax is a functionalized amino acid derivative and a third-generation antiepileptic medicine. It is chemically and mechanistically distinct from older sodium-channel-blocking anticonvulsants such as phenytoin and carbamazepine, giving it a different selectivity profile.

Lacomax is used for the treatment of partial-onset (focal) seizures, either alone or together with other antiepileptic medicines, and is available in oral (tablet, solution) and intravenous forms, allowing flexible use in both outpatient and hospital settings.

Lacomax belongs to the class of antiepileptic drugs (AEDs) / anticonvulsants, specifically classified as a functionalized amino acid with sodium-channel-modulating activity.

Mechanism of Action

The precise mechanism by which Lacosamide exerts its antiepileptic effect is not fully established, but its principal recognized action is to selectively enhance the slow inactivation of voltage-gated sodium channels, without affecting fast inactivation. This stabilizes hyperexcitable neuronal membranes and reduces repetitive neuronal firing associated with seizure activity. This mechanism differs from that of traditional sodium-channel blockers (which primarily affect fast inactivation), which may explain Lacosamide's efficacy in some patients who have not responded to other AEDs.

Lacosamide also binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein involved in neuronal differentiation, although the clinical significance of this binding is not fully understood.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed after oral administration, with bioavailability of approximately 100%; food does not significantly affect absorption.
• Distribution: Low plasma protein binding (less than 15%).
• Metabolism: Metabolized in the liver, partly via CYP2C19, to an inactive metabolite (O-desmethyl lacosamide); metabolism is minor compared with renal elimination of unchanged drug.
• Elimination: Primarily renal, with an elimination half-life of approximately 13 hours; dose adjustment is needed in renal impairment.

Lacomax tablets and oral solution can be taken with or without food, swallowed whole with water (tablets) or measured with an oral dosing device (solution), at consistent times each day (typically twice daily, morning and evening). The intravenous formulation is administered by a healthcare professional as a slow infusion. Do not adjust the dose or frequency without consulting your physician.

Clinically Significant Drug Interactions

• Other PR-interval-prolonging or cardiac conduction-affecting drugs (e.g., beta-blockers, calcium channel blockers, certain antiarrhythmics): concurrent use with Lacomax may increase the risk of cardiac conduction abnormalities (PR prolongation, AV block); caution and ECG monitoring may be warranted.
• Strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): may increase Lacomax plasma concentrations; dose adjustment may be needed, particularly in patients who are poor CYP2C19 metabolizers.
• Strong enzyme inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's Wort): may modestly reduce Lacomax plasma concentrations.
• Other central nervous system depressants (alcohol, sedatives, opioids, benzodiazepines): additive dizziness, sedation, and impaired coordination may occur when combined with Lacomax.

Inform your physician of all medicines, including over-the-counter drugs and supplements, before starting Lacomax.

Common Side Effects

• Dizziness
• Headache
• Nausea and vomiting
• Diplopia (double vision) and blurred vision
• Somnolence (drowsiness)
• Ataxia (unsteady gait, incoordination)
• Fatigue
• Tremor

Serious but Less Common Side Effects

• Cardiac conduction abnormalities: PR interval prolongation, atrioventricular block, bradycardia, and rarely atrial fibrillation/flutter (see Precautions and Warnings).
• Suicidal thoughts or behavior (class effect of antiepileptic drugs; see Precautions and Warnings).
• Multi-organ hypersensitivity reactions (DRESS syndrome) presenting with fever, rash, and organ involvement - requires immediate medical attention.
• Severe dizziness/ataxia leading to falls and injury, particularly in elderly patients.

Pregnancy: Antiepileptic drugs as a class carry potential teratogenic risk, and data on Lacomax in human pregnancy are limited. Lacomax should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close physician supervision; abrupt discontinuation of antiepileptic therapy during pregnancy is not advised due to seizure risk to both mother and fetus. Patients who become pregnant while taking Lacomax are encouraged to enroll in an antiepileptic drug pregnancy registry where available.

Lactation: Lacomax passes into human breast milk. A decision on breastfeeding should be made in consultation with a physician, weighing the benefits of breastfeeding against potential risk to the infant and the mother's clinical need for the drug.

Cardiac Conduction Effects

Lacomax causes dose-dependent prolongation of the PR interval and may cause atrioventricular block, bradycardia, or (rarely) atrial fibrillation or flutter. Caution is advised in patients with known cardiac conduction problems, severe cardiac disease, or those taking other PR-prolonging medications; a baseline ECG may be considered before starting treatment in at-risk patients.

Suicidal Behavior and Ideation

Antiepileptic drugs, including Lacomax, are associated with a small increased risk of suicidal thoughts or behavior. Patients and caregivers should be counseled to monitor for and immediately report any mood changes, depression, or unusual thoughts about self-harm.

Dizziness and Ataxia

Lacomax may cause dizziness, ataxia, and impaired coordination, increasing fall risk, particularly in elderly patients. Patients should be cautious with driving or operating machinery until they know how the medicine affects them.

Abrupt Discontinuation

Lacomax should not be stopped suddenly, as this can precipitate increased seizure frequency or status epilepticus; dose tapering under medical supervision is required.

Multi-Organ Hypersensitivity

Rare but serious multi-organ hypersensitivity reactions (DRESS) have been reported; discontinue immediately and seek medical attention if fever, rash, or lymphadenopathy develop.

Overdose with Lacomax may cause dizziness, nausea, vomiting, cardiac conduction abnormalities (including AV block and arrhythmia), seizures, coma, and respiratory depression. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive and may include cardiac monitoring; hemodialysis may help remove the drug in significant overdose. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze the oral solution or injection.

Renal Impairment

Dose adjustment of Lacomax is recommended in severe renal impairment and end-stage renal disease (maximum 300 mg/day); a supplemental post-dialysis dose may be considered.

Hepatic Impairment

Dose adjustment (maximum 300 mg/day) is recommended for mild to moderate hepatic impairment; use in severe hepatic impairment is not generally recommended due to lack of data.

Elderly

No specific dose adjustment is required based on age alone, but elderly patients may be more susceptible to dizziness, ataxia, falls, and cardiac conduction effects; use with caution and monitor closely.

Pediatric Patients

See Pediatric Uses for approved age ranges and weight-based dosing.

Duration of treatment with Lacomax is individualized by the treating physician based on seizure control, tolerability, and the underlying epilepsy syndrome. Epilepsy treatment with Lacomax is often long-term or indefinite; periodic reassessment is recommended, and any decision to reduce or stop the medicine should be made gradually under medical supervision.

Antiepileptic drug (AED) / anticonvulsant; functionalized amino acid class with selective sodium-channel slow-inactivation-enhancing activity.

Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels in neurons, without affecting fast inactivation. This stabilizes hyperexcitable neuronal membranes and reduces repetitive neuronal firing that underlies seizure activity, offering a mechanism distinct from traditional sodium-channel-blocking antiepileptics.

Lacomax is approved for monotherapy treatment of partial-onset seizures in children aged 4 years and older, and for adjunctive therapy of partial-onset seizures in children aged 1 month and older, and for adjunctive therapy of primary generalized tonic-clonic seizures in children aged 4 years and older with idiopathic generalized epilepsy. Dosing in children is weight-based and must be individualized by a pediatric neurologist or pediatrician experienced in epilepsy management. Safety and efficacy of Lacomax have not been established in children below 1 month of age for any indication, or below 4 years of age for monotherapy use.